Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:
1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.
Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.
Based on those aspects listed above, GuruFocus believes the risk assessment of Prothena is: High Risk: High uncertainty.
Competitive Comparison of Prothena's Risk Assessment
For the Biotechnology subindustry, Prothena's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Prothena's Risk Assessment Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Prothena's Risk Assessment distribution charts can be found below:
* The bar in red indicates where Prothena's Risk Assessment falls into.
Prothena (NAS:PRTA) Risk Assessment Explanation
Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:
(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.
Prothena Risk Assessment Related Terms
Thank you for viewing the detailed overview of Prothena's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.
Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PRTA has been successfully added to your